Exozymes Inc. (EXOZ): Cash & Equivalents

Annual figures by period end, from SEC filings.

$3.04M

As of 2025-12-31

$5.65M

As of 2026-06-30

2023-12-31 Cash & Equivalents (USD) 2025-12-31

Period ended	Cash & Equivalents	Change YoY	Source filing
2025-12-31	$3.04M	-68.7%	2026-03-30, Balance as of period end
2024-12-31	$9.72M	n/m	2026-03-30, Balance as of period end
2023-12-31	$66.5K	n/a	2025-03-31, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cash & Equivalents	Change YoY
Exozymes Inc. (EXOZ)	2025-12-31	$3.04M	-68.7%
AIM ImmunoTech Inc. (AIM)	2025-12-31	$2.98M	+75.5%
Eloxx Pharmaceuticals, Inc. (ELOX)	2025-12-31	$4.79M	n/m
Silexion Therapeutics Corp (SLXN)	2025-12-31	$5.99M	+404.7%
VivoSim Labs, Inc. (VIVS)	2026-03-31	$5.02M	-55.6%
Tevogen Inc. (TVGN)	2025-12-31	$0	n/a
Calidi Biotherapeutics, Inc. (CLDI)	2024-12-31	$9.60M	n/a
Greenland Mines Ltd (GRML)	2025-12-31	$7.18M	n/m
Dyadic International Inc (DYAI)	2025-12-31	$4.62M	-29.0%

Compare EXOZ, AIM, ELOX, SLXN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗